×
About 1,505 results

ALLMedicine™ Chromogranin A Center

Research & Reviews  559 results

Colorectal paragangliomas with immunohistochemical deficiency of succinate dehydrogenas...
https://doi.org/10.1507/endocrj.EJ21-0630
Endocrine Journal; Kimura N, Ishikawa M et. al.

Dec 3rd, 2021 - Recent progress in paraganglioma (PGL) revealed genotype-phenotype relationship, especially succinate dehydrogenase complex subunit B (SDHB) gene mutation-related to the extra-adrenal origin and metastasis. SDHB-immunohistochemistry can detect all...

Gastric Adenocarcinoma of the Fundic Gland Type: A Case Report.
https://doi.org/10.12659/AJCR.933474
The American Journal of Case Reports; Kakumoto A, Kuroda H et. al.

Dec 3rd, 2021 - BACKGROUND Gastric adenocarcinoma of the fundic gland type (GAFG) is an extremely rare neoplasm that consists of a mixed proliferation of oxyntic and chief cells. Differential diagnosis of GAFG is difficult in the absence of infiltration. Here, we...

Putative regulation of macrophage-mediated inflammation by catestatin.
https://doi.org/10.1016/j.it.2021.11.002
Trends in Immunology; Muntjewerff EM, Christoffersson G et. al.

Dec 1st, 2021 - Catestatin (CST) is a bioactive cleavage product of the neuroendocrine prohormone chromogranin A (CgA). Recent findings show that CST can exert anti-inflammatory and antiadrenergic effects by suppressing the inflammatory actions of mammalian macro...

Spindle cell variant of medullary thyroid carcinoma: a clinicopathologic study of four ...
https://doi.org/10.1186/s13000-021-01152-w 10.1159/000328348 10.1002/dc.20656 10.1007/s10147-013-0588-8 10.1089/thy.2014.0335 10.1309/4DQW6RQX3C6KRX1J
Diagnostic Pathology; Wang YX, Yang SJ

Nov 29th, 2021 - Medullary thyroid carcinoma (MTC) is a malignant tumor derived from C cells. It accounts for about 10% of all thyroid malignancies. More than 14 histological variants have been described. Among them, spindle cell variant is extremely rare. Here we...

see more →

Guidelines  3 results

Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline for Pr...
https://doi.org/10.1227/NEU.0000000000001387
Neurosurgery Fleseriu M, Bodach ME et. al.

Sep 17th, 2016 - Nonfunctioning pituitary adenomas (NFPAs) are among the most common pituitary lesions and may present with hypopituitarism and/or hyperprolactinemia. To review the existing literature as it pertains to preoperative endocrine assessment in the work...

Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expe...
https://doi.org/10.1093/annonc/mdv041
Annals of Oncology : Official Journal of the European Soc... Caplin ME, Baudin E et. al.

Feb 4th, 2015 - Pulmonary carcinoids (PCs) are rare tumors. As there is a paucity of randomized studies, this expert consensus document represents an initiative by the European Neuroendocrine Tumor Society to provide guidance on their management. Bibliographical ...

The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis a...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419007
Pancreas Chen H, Sippel RS et. al.

Jul 29th, 2010 - Pheochromocytomas, intra-adrenal paraganglioma, and extra-adrenal sympathetic and parasympathetic paragangliomas are neuroendocrine tumors derived from adrenal chromaffin cells or similar cells in extra-adrenal sympathetic and parasympathetic para...

see more →

Drugs  10 results see all →

Clinicaltrials.gov  13 results

Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
https://clinicaltrials.gov/ct2/show/NCT01229943

Sep 9th, 2021 - PRIMARY OBJECTIVES: l. To assess the progression-free survival rate of patients with locally advanced or metastatic pancreatic neuroendocrine tumors treated with everolimus alone or everolimus plus bevacizumab. SECONDARY OBJECTIVES: I. To compare ...

Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors
https://clinicaltrials.gov/ct2/show/NCT01782443

Jun 22nd, 2021 - If you are willing to participate in this study you will be asked to undergo some screening tests and procedures to confirm that you are eligible. Many of these tests and procedures are likely to be part of regular cancer care and may be done even...

Evaluation of Neuroendocrine Differentiation as a Potential Mechanism of Tumor Recurrence Following Radiotherapy in Prostate Carcinoma
https://clinicaltrials.gov/ct2/show/NCT03017794

Jan 12th, 2021 - Neuroendocrine differentiation (NED) in prostate cancer is a well-recognized phenotypic change by which prostate cancer cells transdifferentiate into neuroendocrine-like (NE-like) cells. Accumulated evidences have suggested that the prevalence of ...

Identification of Novel Molecular Targets for Rheumatoid Arthritis Patients
https://clinicaltrials.gov/ct2/show/NCT04201535

Dec 17th, 2019 - The general aim is to study the mechanisms of the dissociation between the inflammatory activity and the joints destruction in patients with rheumatoid arthritis (RA) in remission but presenting a progression of the bone erosions. The primary aim ...

Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
https://clinicaltrials.gov/ct2/show/NCT01967537

Nov 19th, 2019 - Background: Neuroendocrine tumors (NETs) are rare malignancies occurring in the gastrointestinal tract, islets of the pancreas, lung, adrenal medulla and thyroid C-cells. Their incidence has increased over the last decade, with an incidence of 6 p...

see more →

News  16 results

Colchicine Promising for Autoimmune Pancreatitis?
https://www.medpagetoday.com/gastroenterology/pancreaticdiseases/94956

Oct 11th, 2021 - Treatment with the anti-inflammatory drug colchicine resolved recurrent type 2 autoimmune pancreatitis (AIP) in patients who previously received other drugs, a case series in Italy found. Two patients with type 2 AIP experienced clinical improveme...

Accurately Diagnosing NETs
https://www.onclive.com/view/accurately-diagnosing-nets

Apr 2nd, 2021 - Transcript: Jonathan R. Strosberg, MD: Simron, can you talk a little about what kinds of symptoms patients sometimes present with? And what are the unique challenges of working up patients with NETs [neuroendocrine tumors]? Simron Singh, MD...

Current and Emerging Treatments for Gastroenteropancreatic Neuroendocrine Tumors
https://www.onclive.com/view/current-and-emerging-treatments-for-gastroenteropancreatic-neuroendocrine-tumors

Dec 5th, 2020 - Approximately 175,000 Americans are affected by neuroendocrine tumors (NETs), 65% of which are gastroenteropancreatic (GEP) NETs. GEP-NETs represent a diverse family of tumors that arise in the gastrointestinal (GI) tract or pancreas.1-3 The overa...

IPCC Case-Based Discussion: How Should We Sequence Therapy?
https://www.onclive.com/view/ipcc-case-based-discussion-how-should-we-sequence-therapy

Dec 5th, 2020 - A multidisciplinary audience gathered in New York City for the 5th Annual Interdisciplinary Prostate Cancer Congress. The meeting provided an opportunity for medical oncologists, radiation oncologists, and urologists to review the latest strategie...

Prognostic Factors for Progression of Neuroendocrine Tumors Identified in Reanalysis of RADIANT-2
https://www.onclive.com/view/prognostic-factors-for-progression-of-neuroendocrine-tumors-identified-in-reanalysis-of-radiant-2

Dec 5th, 2020 - James Yao, MD The placebo-controlled phase III RADIANT-2 trial showed that the addition of everolimus to standard octreotide LAR achieved about a 5-month improvement in progression-free survival (PFS) in patients with advanced neuroendocrine...

see more →

Patient Education  1 results see all →